Clinical trial
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine…
NCT00226941 · George Albert Fisher, Other · Terminated
Key facts
| NCT number | NCT00226941 |
|---|---|
| Title | A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer |
| Official title | A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgical Resection for Locally-Advanced Rectal Cancer |
| Lead sponsor | George Albert Fisher, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Rectal Cancer, Colo-rectal Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Cetuximab, Oxaliplatin, Capecitabine, Radiotherapy, Diphenhydramine hydrochloride (HCl) |
| Enrollment | 23 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Sep 27, 2005 |
| Last update posted | Dec 8, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: